A study to Find Out if the Products Can Cause Skin Pore Blockage

Evaluation of comedogenicity potential of the investigational products by follicular biopsy test - NIL

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/04/109409

Enrollment

Registered

2026-04-27

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: SKIN LIGHTENING SERUM: Product will be applied topically under occlusive condition on the skin from visit 2 to Visit 13 Control Intervention1: Negative control 1: 0.9% saline Control In

Eligibility

Inclusion criteria

Inclusion criteria: 1. Male or female trial participants 18 to 65 years of age. 2. Trial participants must be generally in good health as determined by a recent medical history which is on file with the investigator. 3. The ability of the trial participant to understand and sign a written informed consent form which must be obtained before treatment. 4. Willingness to avoid the use of topical products at the test sites during the study. 5. Trial participants known to have comedogenic skin. Trial participants who are prone to acne and skin break-outs. 6. Presence of micro-comedones at the screening visit.

Exclusion criteria

Exclusion criteria: 1. Individuals with an active or history of psoriasis, active allergic skin responses, or active eczema as determined by the initial paperwork. Individuals with a history of eczema will be allowed to the study, as long as they complete a supplemental consent form. 2. Individuals with sunburn, abrasions, scar tissue, or tattoos on the test sites, or diseases of the skin that might interfere with the evaluation made in this study or that expose study participants to unacceptable risks. 3. Women known to be pregnant, nursing, or planning to become pregnant during the study as determined by the initial paperwork. 4. Use of topical steroids and/or drugs at test sites as determined by the initial paperwork. 5. Current routine or frequent use of high doses of anti-inflammatory drugs for a defined medical condition as determined by medical history. 6. Trial participants who are employed at CRO or with the sponsor

Design outcomes

Primary

Measure	Time frame
To determine comedogenic potential of the test product when applied topically under occlusive condition on the skin of human trial participantsTimepoint: Day 1, Day 2, Day 4, Day6, Day 9, Day 11, Day 13, Day16, Day18, Day20, Day 23, Day 25, Day 27, Day28.	—

Secondary

Measure	Time frame
NilTimepoint: Nil	—

Countries

India

Contacts

Public ContactSudhanthiran S

MS Clinical Research Pvt. Ltd

ritambhara@msclinical.com08040917253

Outcome results